HIV has proven a hard target for vaccine design. The most promising approach, germline-targeting (GT), proposes a series of immunizations: a first shot to activate inexperienced B ...

During the late phase of HIV type 1 (HIV-1) infection cycle, the virally encoded Gag polyproteins are targeted to the inner leaflet of the plasma membrane (PM) for assembly, formation of immature ...

Researchers from the California Institute of Technology and collaborating institutions have developed a novel HIV vaccine candidate, a new germline-targeting Env SOSIP trimer called 3nv.2, that is ...

The ideal HIV vaccine would elicit humoral responses effective against a broad spectrum of primary HIV strains but immunogens capable of generating such antibodies in humans have been difficult to ...

Researchers at Fred Hutchinson Cancer Center, led by Dr. Julie McElrath, Director of the Vaccine and Infectious Disease Division, have found a new way to train our immune system to make antibodies ...

To mark the occasion of World AIDS Day, Dr. Madeleine Durand and Andrés Finzi are working to reduce chronic inflammation and the risk of comorbidities in people living with HIV. The human ...

New HIV vaccines have shown promise in studies with lab animals and human volunteers, pointing to a potential way of preventing the lifelong viral disease. These experimental vaccines are built upon ...

Though not a full vaccine yet, discovery shows important proof of concept that can neutralize a third of the strains of HIV in the U.S. The human immunodeficiency virus (HIV) is one of the most common ...

HIV infects immune cells and establishes long-lasting infections that can progress to acquired immunodeficiency syndrome (AIDS) if left untreated. With the advancement of antiviral therapy (ART), HIV ...